{"id":194905,"date":"2026-07-20T06:13:27","date_gmt":"2026-07-20T11:43:27","guid":{"rendered":"https:\/\/newslink360.space\/?p=194905"},"modified":"2026-07-20T06:13:27","modified_gmt":"2026-07-20T11:43:27","slug":"takedas-qdenga-approved-in-india-can-be-given-despite-pre-exposure-to-dengue","status":"publish","type":"post","link":"https:\/\/newslink360.space\/?p=194905","title":{"rendered":"Takeda\u2019s QDENGA approved in India, can be given despite pre-exposure to dengue"},"content":{"rendered":"<p><br \/>\n<\/p>\n<div id=\"ControlPara\" itemprop=\"articleBody\">Takeda Biopharmaceuticals India has received market authorisation from the Indian drug regulatory authority for QDENGA, its dengue vaccine for prevention of the disease in the 4\u201360 years age group. It is the first dengue vaccine approved in India that can be used in individuals regardless of previous dengue exposure, without the need for pre-vaccination testing, the multinational healthcare company said.<\/p>\n<p>Dengue is a mosquito-borne viral disease, and a global public health threat, with prevalence in over 125 countries. India accounts for nearly one-third of the global dengue burden,\u00a0a note from the company said. In 2025, reported cases exceeded 113,000, but modelling analyses suggest the dengue burden in India appears to be higher than reported, likely representing tens of millions of infections each year, it added.<\/p>\n<p>QDENGA is a tetravalent, live-attenuated vaccine designed to provide protection across all four dengue virus serotypes. It is administered subcutaneously as a 0.5 mL as a two-dose regimen, with doses given three months apart. Recommended by the WHO for use in dengue-endemic settings, the vaccine had received WHO prequalification, a couple of years ago.<\/p>\n<p>The approval in India is based on results from Takeda\u2019s global clinical development program, involving 19 Phase 1, 2 and 3 clinical trials with over 28,000 participants in both endemic and non-endemic regions, the company said. This included the pivotal Phase III TIDES (DEN-301) trial, which evaluated the vaccine in over 20,000 participants across eight countries over an extended period to evaluate both the long-term safety and efficacy of QDENGA, it added.<\/p>\n<p>The approval is also supported by data from a Phase III clinical trial (DEN-302) conducted in Indian participants, which evaluated the safety and immunogenicity of the vaccine in individuals aged 4\u201360 years, the company said. \u201cThe study demonstrated that QDENGA was found to be tolerated, safe and immunogenic in healthy adults, adolescents and children. These clinical outcomes are further supported by real-world evidence generation and ongoing pharmacovigilance to deepen understanding of the vaccine\u2019s safety and impact,\u201d it added.\u00a0<b\/>\u00a0<\/p>\n<p>Mahender Nayak, Takeda\u2019s Head of Intercontinental Markets said, \u201cDengue is a growing public health challenge, and India needs sustained, evidence-based prevention. The latest seven-year data for QDENGA show continued protection against dengue infection and hospitalisation across all four serotypes; an important milestone for communities and health systems.\u201d Since its launch in 2022, QDENGA has been approved in 43 countries, with more than 32 million doses distributed globally, he said.<\/p>\n<p>Peter Streibl, General Manager, Southeast Asia and India Cluster added, \u201cDengue is a shared regional challenge that requires collaboration across borders and sectors. Takeda is committed to working with governments, public health authorities, healthcare professionals, and partners across South and Southeast Asia, not only to support access to QDENGA, where approved and recommended, but also to strengthen broader dengue prevention efforts, including surveillance, awareness, vector control, and community engagement.\u201d<\/p>\n<p>Goh Choo Beng, Medical Affairs Head Southeast Asia and India Cluster<b\/>said,\u00a0<i>\u201c<\/i>India carries a substantial dengue burden, and all four dengue virus serotypes have been documented as co-circulating in several regions. QDENGA is designed to protect against all four serotypes, regardless of prior exposure.\u201d<\/p>\n<p>QDENGA has been approved in\u00a043 countries across Asia, Latin America and Europe, including India, with more than\u00a032 million doses distributed globally through public and private programs, it said.<\/p>\n<p class=\"publish-time\" id=\"end-of-article\">Published on  July 20, 2026 <\/p>\n<\/div>\n<p><br \/>\n<br \/><a href=\"https:\/\/www.thehindubusinessline.com\/news\/national\/takedas-qdenga-approved-in-india-can-be-given-despite-pre-exposure-to-dengue\/article71244817.ece\" target=\"_blank\" rel=\"noopener\">Source link <\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Takeda Biopharmaceuticals India has received market authorisation from the Indian drug regulatory authority for QDENGA, its dengue vaccine for prevention of the disease in the 4\u201360 years age group. It is the first dengue vaccine approved in India that can be used in individuals regardless of previous dengue exposure, without the need for pre-vaccination testing,&#8230;<\/p>\n","protected":false},"author":1,"featured_media":194906,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7],"tags":[],"class_list":["post-194905","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-national-news"],"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/newslink360.space\/wp-content\/uploads\/2026\/07\/IMG_BL30_BUZZ2_2_1_JN8TQQUS.jpg","jetpack_likes_enabled":true,"jetpack-related-posts":[{"id":195070,"url":"https:\/\/newslink360.space\/?p=195070","url_meta":{"origin":194905,"position":0},"title":"India approves first dengue vaccine for people aged 4-60 years \u2013 Asia News Network","author":"Ajay Kumar Verma","date":"July 20, 2026","format":false,"excerpt":"July 21, 2026 NEW DELHI \u2013 In a major breakthrough, India has approved its first dengue vaccine, with the Drug Controller General of India (DCGI) granting market authorisation to QDENGA from Takeda Biopharmaceuticals India. The vaccine was approved for individuals aged between 4 and 60 years. It can be administered\u2026","rel":"","context":"In &quot;National News&quot;","block_context":{"text":"National News","link":"https:\/\/newslink360.space\/?cat=7"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/newslink360.space\/wp-content\/uploads\/2026\/07\/AFP__20260227__94FG9WK__v1__MidRes__IndiaHealthVaccinesDengue.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/newslink360.space\/wp-content\/uploads\/2026\/07\/AFP__20260227__94FG9WK__v1__MidRes__IndiaHealthVaccinesDengue.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/newslink360.space\/wp-content\/uploads\/2026\/07\/AFP__20260227__94FG9WK__v1__MidRes__IndiaHealthVaccinesDengue.jpg?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/newslink360.space\/wp-content\/uploads\/2026\/07\/AFP__20260227__94FG9WK__v1__MidRes__IndiaHealthVaccinesDengue.jpg?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/newslink360.space\/wp-content\/uploads\/2026\/07\/AFP__20260227__94FG9WK__v1__MidRes__IndiaHealthVaccinesDengue.jpg?resize=1050%2C600&ssl=1 3x"},"classes":[]},{"id":196716,"url":"https:\/\/newslink360.space\/?p=196716","url_meta":{"origin":194905,"position":1},"title":"India&#8217;s First Dengue Vaccine Is Here: Who Should Get It And What You Need To Know","author":"Ajay Kumar Verma","date":"July 24, 2026","format":false,"excerpt":"India has approved its first dengue vaccine, marking a significant milestone in the country's efforts to combat one of its most persistent mosquito-borne diseases. The Central Drugs Standard Control Organisation (CDSCO) has granted marketing authorisation for Qdenga, a live, attenuated tetravalent dengue vaccine, making it the first vaccine approved in\u2026","rel":"","context":"In &quot;National News&quot;","block_context":{"text":"National News","link":"https:\/\/newslink360.space\/?cat=7"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/newslink360.space\/wp-content\/uploads\/2026\/07\/imresizer-pexels-jorgemendoza80-9344579_20260725093022_ogImage_47.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/newslink360.space\/wp-content\/uploads\/2026\/07\/imresizer-pexels-jorgemendoza80-9344579_20260725093022_ogImage_47.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/newslink360.space\/wp-content\/uploads\/2026\/07\/imresizer-pexels-jorgemendoza80-9344579_20260725093022_ogImage_47.jpg?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/newslink360.space\/wp-content\/uploads\/2026\/07\/imresizer-pexels-jorgemendoza80-9344579_20260725093022_ogImage_47.jpg?resize=700%2C400&ssl=1 2x"},"classes":[]},{"id":194952,"url":"https:\/\/newslink360.space\/?p=194952","url_meta":{"origin":194905,"position":2},"title":"Type 2 Diabetes Patients Face Higher Risk of Severe Dengue Complications: Study","author":"Ajay Kumar Verma","date":"July 20, 2026","format":false,"excerpt":"People living with Type 2 diabetes face a significantly higher risk of developing severe and potentially life-threatening complications from dengue infection, according to a new review by leading diabetes specialists. The paper also recommends integrating dengue vaccination into routine diabetes care to better protect high-risk patients in dengue-endemic regions. The\u2026","rel":"","context":"In &quot;National News&quot;","block_context":{"text":"National News","link":"https:\/\/newslink360.space\/?cat=7"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/newslink360.space\/wp-content\/uploads\/2026\/07\/Type-2-Diabetes-Patients-Face-Higher-Risk-of-Severe-Dengue-Complications-Study.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/newslink360.space\/wp-content\/uploads\/2026\/07\/Type-2-Diabetes-Patients-Face-Higher-Risk-of-Severe-Dengue-Complications-Study.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/newslink360.space\/wp-content\/uploads\/2026\/07\/Type-2-Diabetes-Patients-Face-Higher-Risk-of-Severe-Dengue-Complications-Study.jpg?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/newslink360.space\/wp-content\/uploads\/2026\/07\/Type-2-Diabetes-Patients-Face-Higher-Risk-of-Severe-Dengue-Complications-Study.jpg?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/newslink360.space\/wp-content\/uploads\/2026\/07\/Type-2-Diabetes-Patients-Face-Higher-Risk-of-Severe-Dengue-Complications-Study.jpg?resize=1050%2C600&ssl=1 3x"},"classes":[]},{"id":195050,"url":"https:\/\/newslink360.space\/?p=195050","url_meta":{"origin":194905,"position":3},"title":"Type 2 diabetes may raise risk of severe dengue, warns review","author":"Ajay Kumar Verma","date":"July 20, 2026","format":false,"excerpt":"4 min readNew DelhiJul 21, 2026 06:00 AM IST People with Type 2 diabetes face a higher risk of severe, life-threatening dengue complications, according to a review paper slated for publication in the International Journal of Diabetes & Technology, which calls for integrating dengue vaccination into routine diabetes care to\u2026","rel":"","context":"In &quot;National News&quot;","block_context":{"text":"National News","link":"https:\/\/newslink360.space\/?cat=7"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/newslink360.space\/wp-content\/uploads\/2026\/07\/diabetes-dengue_1600.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/newslink360.space\/wp-content\/uploads\/2026\/07\/diabetes-dengue_1600.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/newslink360.space\/wp-content\/uploads\/2026\/07\/diabetes-dengue_1600.jpg?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/newslink360.space\/wp-content\/uploads\/2026\/07\/diabetes-dengue_1600.jpg?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/newslink360.space\/wp-content\/uploads\/2026\/07\/diabetes-dengue_1600.jpg?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/newslink360.space\/wp-content\/uploads\/2026\/07\/diabetes-dengue_1600.jpg?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":193198,"url":"https:\/\/newslink360.space\/?p=193198","url_meta":{"origin":194905,"position":4},"title":"Who is Jordan Brown? US national under scanner for trying to cross India-Nepal border","author":"Ajay Kumar Verma","date":"July 13, 2026","format":false,"excerpt":"Investigators are questioning an American citizen who was arrested by the Sashastra Seema Bal (SSB) at the India-Nepal border on Saturday while allegedly attempting to cross into Nepal without valid travel documents. Officials said multiple central intelligence and security agencies have questioned him.An American citizen, identified as Jordan Brown from\u2026","rel":"","context":"In &quot;National News&quot;","block_context":{"text":"National News","link":"https:\/\/newslink360.space\/?cat=7"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/newslink360.space\/wp-content\/uploads\/2026\/07\/ANI-20260713139-0_1783995344091_1783995352367_5978bc73-46ea-44ce-8029-2e1a4241d6c1.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/newslink360.space\/wp-content\/uploads\/2026\/07\/ANI-20260713139-0_1783995344091_1783995352367_5978bc73-46ea-44ce-8029-2e1a4241d6c1.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/newslink360.space\/wp-content\/uploads\/2026\/07\/ANI-20260713139-0_1783995344091_1783995352367_5978bc73-46ea-44ce-8029-2e1a4241d6c1.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]},{"id":196157,"url":"https:\/\/newslink360.space\/?p=196157","url_meta":{"origin":194905,"position":5},"title":"US unveils fresh tariffs of up to 12.5% on 60 economies amid &#8216;forced labour&#8217; probe; rate for India lowered to 10%","author":"Ajay Kumar Verma","date":"July 23, 2026","format":false,"excerpt":"India to face 10% US tarrifs The Trump administration on Thursday imposed new tariffs of 10 per cent and 12.5 per cent on imports from 60 economies, including India, saying the move aims to push trading partners to strengthen enforcement against goods produced using forced labour. India now qualifies for\u2026","rel":"","context":"In &quot;National News&quot;","block_context":{"text":"National News","link":"https:\/\/newslink360.space\/?cat=7"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/newslink360.space\/wp-content\/uploads\/2026\/07\/1784846474_photo.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/newslink360.space\/wp-content\/uploads\/2026\/07\/1784846474_photo.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/newslink360.space\/wp-content\/uploads\/2026\/07\/1784846474_photo.jpg?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/newslink360.space\/wp-content\/uploads\/2026\/07\/1784846474_photo.jpg?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/newslink360.space\/wp-content\/uploads\/2026\/07\/1784846474_photo.jpg?resize=1050%2C600&ssl=1 3x"},"classes":[]}],"jetpack_sharing_enabled":true,"jetpack_shortlink":"https:\/\/wp.me\/pgnRh4-OHD","_links":{"self":[{"href":"https:\/\/newslink360.space\/index.php?rest_route=\/wp\/v2\/posts\/194905","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/newslink360.space\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/newslink360.space\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/newslink360.space\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/newslink360.space\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=194905"}],"version-history":[{"count":0,"href":"https:\/\/newslink360.space\/index.php?rest_route=\/wp\/v2\/posts\/194905\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/newslink360.space\/index.php?rest_route=\/wp\/v2\/media\/194906"}],"wp:attachment":[{"href":"https:\/\/newslink360.space\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=194905"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/newslink360.space\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=194905"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/newslink360.space\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=194905"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}